Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 414

NCT06037252

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Tirzepatide High Dose 1n/rn/rn/rn/r
Tirzepatide High Dose 2n/rn/rn/rn/r
Tirzepatiden/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Tirzepatide High Dose 1: endpoint not reported
  • Tirzepatide High Dose 2: endpoint not reported
  • Tirzepatide: endpoint not reported
  • Placebo: endpoint not reported